Dot1L-IN-5

Name: Dot1L-IN-5
Brand: TargetMol
SKU: T11084
Rating: 4.5 (1 reviews)

还可以

产品编号 T11084Cas号 2565705-03-3

Dot1L-IN-5 是强效的类端粒沉默干扰体 1 (DOT1L) 抑制剂，IC50 SPA DOT1L 为 0.17 nM。

还可以

产品编号 T11084Cas号 2565705-03-3

Dot1L-IN-5 是强效的类端粒沉默干扰体 1 (DOT1L) 抑制剂，IC50 SPA DOT1L 为 0.17 nM。

大包装 & 定制

加入购物车

该分子属于定制产品。TargetMol拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

实验操作小课堂

常见问题解答

Dot1L-IN-5 相关产品

产品介绍

生物活性

产品描述	Dot1L-IN-5 is a potent inhibitor of the disruptor of telomeric silencing 1-like protein ( DOT1L ) with an IC 50 SPA DOT1L of 0.17 nM [1].
靶点活性	DOT1L:0.17 nM
体外活性	Dot1L-IN-5 (Compound 11) is tested in cellular assays in order to assess the ability to inhibit the dimethylation of H3K79 in HeLa cells (ED 50 H3K79me2 Elisa =2.9 nM) and HOXA9 gene expression in Molm-13 cells (ED 50 HOXA9 RGA =30 nM) [1].
体内活性	Dot1L-IN-5 (Compound 11; subcutaneous injection; at 75 mg/kg once daily for 20 days) does not lead to tumor growth inhibition in NOD-SCID mice. Dot1L-IN-5 (subcutaneous injection; at 75 mg/kg twice daily for 20 days) leads 73% growth inhibition [1]. While both treatment regimens cause very strong inhibition of global H3K79 dimethylation level in tumor, the efficacious regimen is superior in reducing the mRNA expression of the target genes HOXA9 and MEIS1 [1]. Animal Model: NOD-SCID mice bearing subcutaneous MV4-11 tumor xenografts [1] Dosage: 75 mg/kg Administration: Subcutaneous injection; at 75 mg/kg once or twice daily for 20 days Result: Once daily administration did not lead to tumor growth inhibition, 73% growth inhibition was measured in the twice daily treated group.